收缩压与脉压在心力衰竭中的汇总分析:四项试验的参与者水平数据
该研究汇总了I-PRESERVE、TOPCAT-Americas、PARAGON-HF和DELIVER四项随机试验中16950例HFmrEF/HFpEF患者的数据,分析基线收缩压(SBP)和脉压(PP)与主要终点(首次心衰住院或心血管死亡)的关系。结果显示SBP和PP与主要终点均呈J型曲线关系,SBP最低风险在120-130 mmHg,PP最低风险在50-60 mmHg;最高SBP类别(≥140 mmHg)和最高PP四分位均与主要终点风险升高相关(HR分别为1.22)。
要点
- HFmrEF/HFpEF患者基线SBP与主要终点呈J型关系,最低风险在120-130 mmHg。
- 脉压与主要终点也呈J型关系,最低风险在50-60 mmHg。
- 脉压升高与心血管风险增加相关,且不受SBP水平影响。
核心结论
- 在HFmrEF/HFpEF患者中,基线收缩压和脉压与心血管风险均呈J型关系。
- 收缩压120-130 mmHg和脉压50-60 mmHg时风险最低。
研究设计与样本
- 汇总分析四项全球随机临床试验(I-PRESERVE、TOPCAT-Americas、PARAGON-HF、DELIVER)的参与者水平数据。
- 共纳入16950例左室射血分数≥40%(DELIVER)或≥45%(其他试验)的心衰患者。
- 采用限制性立方样条分析连续基线SBP和PP与主要终点(首次心衰住院或心血管死亡)的关系。
主要发现
- 平均年龄71±9岁,49%为男性,平均SBP 131±15 mmHg,平均PP 55±14 mmHg。
- SBP与主要终点呈J型关系,最低风险在120-130 mmHg。
- PP与主要终点呈类似J型关系,最低风险在50-60 mmHg。
- 以SBP 120-129 mmHg为参照,最高SBP类别(≥140 mmHg)与主要终点风险升高相关(HR 1.22;95% CI 1.10-1.34)。
- 以PP 46-54 mmHg为参照,最高PP四分位与主要终点风险升高相关(HR 1.22;95% CI 1.11-1.34),且较高PP与更高心血管风险相关,不受SBP影响。
临床怎么用
- 对于HFmrEF/HFpEF患者,管理血压时需关注SBP和PP,SBP目标可能以120-130 mmHg为宜。
- 脉压升高可作为心血管风险增高的标志,即使SBP控制尚可也应重视。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hypertension is common in patients with heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF), and current guidelines recommend treating systolic blood pressure (SBP) to a target <130 mm Hg. However, data supporting treatment to this target are limited. Additionally, pulse pressure (PP), a marker of aortic stiffness, has been associated with increased risk of cardiovascular events, but its prognostic impact in HFpEF has not been extensively studied. OBJECTIVES: This study aimed to explore the impact of baseline SBP and PP on cardiovascular outcomes in patients with HFmrEF or HFpEF. METHODS: The I-PRESERVE (Irbesartan in Heart Failure With Preserved Ejection Fraction), TOPCAT (Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist)-Americas, PARAGON-HF (Prospective Comparison of Angiotensin Receptor-Neprilysin Inhibitor With Angiotensin-Receptor Blocker Global Outcomes in HF With Preserved Ejection Fraction), and DELIVER (Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure) trials were global, randomized clinical trials testing irbesartan, spironolactone, sacubitril/valsartan, and dapagliflozin, respectively, against either a placebo or an active comparator (valsartan, in PARAGON-HF), in patients with heart failure and a left ventricular ejection fraction ≥40% (in DELIVER) or ≥45% (in the other trials). The relationship between continuous baseline SBP and PP, and the primary endpoint (first heart failure hospitalization or cardiovascular death) was analyzed with restricted cubic splines. We further evaluated the prognostic impact of SBP categories (<120, 120-129, 130-139, and ≥140 mm Hg) and PP quartiles on the primary endpoint. RESULTS: A total of 16,950 patients (mean age 71 ± 9 years; 49% male; mean SBP 131 ± 15 mm Hg; mean PP 55 ± 14 mm Hg) were included. The relationship between SBP and the primary endpoint was J-shaped, with the lowest risk at 120 to 130 mm Hg. A similar pattern was found for PP, with the lowest risk at 50 to 60 mm Hg. The highest SBP category (reference: 120-129 mm Hg) and PP quartile (reference: 46-54 mm Hg) were associated with a higher risk of the primary outcome (HR: 1.22; 95% CI: 1.10-1.34 and HR: 1.22; 95% CI: 1.11-1.34, respectively). Higher PP was associated with greater cardiovascular risk, regardless of SBP. CONCLUSIONS: Our analysis of a large pooled dataset from 4 clinical trials, including >16,900 patients with HFmrEF/HFpEF, indicates a J-shaped relationship between both SBP and PP and cardiovascular risk. The lowest risk was observed at SBP levels between 120 and 130 mm Hg and PP values between 50 and 60 mm Hg (I-PRESERVE [Irbesartan in Heart Failure With Preserved Systolic Function], NCT00095238; TOPCAT [Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist], NCT00094302; PARAGON-HF [Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction], NCT01920711; DELIVER [Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure], NCT03619213).
引用
- Lu, Kondo, Claggett, et al. Systolic Blood Pressure and Pulse Pressure in Heart Failure: Pooled Participant-Level Analysis of 4 Trials. J Am Coll Cardiol. 2024. PMID: 39745404. doi:10.1016/j.jacc.2024.11.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。